Details

RNA as a Drug Target


RNA as a Drug Target

The Next Frontier for Medicinal Chemistry
Methods & Principles in Medicinal Chemistry 1. Aufl.

von: John Schneekloth, Martin Pettersson, Raimund Mannhold, Helmut Buschmann, Jörg Holenz

142,99 €

Verlag: Wiley-VCH (D)
Format: PDF
Veröffentl.: 26.06.2024
ISBN/EAN: 9783527840434
Sprache: englisch
Anzahl Seiten: 416

DRM-geschütztes eBook, Sie benötigen z.B. Adobe Digital Editions und eine Adobe ID zum Lesen.

Beschreibungen

<p><b>Discover a new paradigm in drug discovery that greatly expands the space of addressable drug targets and potential novel drugs</b> <p>Existing paradigms for drug discovery have focused largely on enzymes and other proteins as drug targets. In recent years, however, different varieties of ribonucleic acids have emerged as a viable focus for target-based drug discovery, with the potential to revolutionize the strategy and approach for this essential step in the drug development process. <p><i>RNA as a Drug Target: The Next Frontier for Medicinal Chemistry </i>offers a practice-oriented introduction to developing drug-like small molecules that selectively modulate both coding and non-coding RNAs. Beginning with a description and characterization of existing druggable RNAs, the book discusses how to approach different RNA targets for drug discovery. The result is a crucial resource for targeting RNAs and creating the next generation of life-saving pharmaceuticals. <p><i>RNA as a Drug Target </i>readers will also find: <ul><li>A complete “toolbox” for working with RNA, from structure determination to screening and lead generation techniques</li> <p><li>A wide range of addressable targets and mechanisms, including splicing modulation, riboswitches, targeted degradation, and more</li> <p><li>Authoritative discussion of the potential of RNA-targeted small molecule therapeutics for drugging the epitranscriptome</li></ul> <p><i>RNA as a Drug Target</i> provides an expert introduction to a new frontier in pharmaceutical research for medicinal chemists, biochemists, molecular biologists, and members of the pharmaceutical industry.
<p>1. Introduction </p> <p>2. RNA Structure Probing, Dynamics, Folding </p> <p>3. High Resolution Structures of RNA </p> <p>4. Screening and Lead Generation Techniques for RNA Binders </p> <p>5. Chemical Matter that Binds RNA </p> <p>6. MicroRNAs as Targets for Small Molecule Binders </p> <p>7. Pre-mRNA Splicing Modulation </p> <p>8. Prospects for Riboswitches in Drug Development </p> <p>9. Small Molecules That Degrade RNA </p> <p>10. Approaches to the Identification of Molecules Altering Programmed Ribosomal Frameshifting in Viruses </p> <p>11. RNA-Protein Interactions: A New Approach for Drugging RNA Biology </p> <p>12. Drugging the Epitranscriptome </p> <p>13. A Perspective on RNA: The Next Frontier for Small Molecule Therapeutics </p>
<p><b>John Schneekloth, Jr., PhD (Jay),</b> obtained his PhD from the chemistry department of Yale University. Following postdoctoral work at Princeton, Dr. Schneekloth joined the NCI, where his research involves using synthetic chemistry and high throughput chemical biology approaches to develop chemical probes of RNA, with a particular emphasis on targeting RNA with druglike small molecules.</p> <p><b>Martin Pettersson, PhD,</b> obtained his PhD in Organic Chemistry from the University of Texas at Austin. He is a medical chemistry / drug discovery leader with over 20 years of industrial experience, mainly with Pfizer (co-inventor of Paxlovid). He has then continued as Senior Director of Neuroscience/Pain, Chemistry, at Grünenthal Boston Innovation Hub, and most recently as VP of Drug Discovery at Promedigen in South Korea.</p>
<p><b>Discover a new paradigm in drug discovery that greatly expands the space of addressable drug targets and potential novel drugs</b> <p>Existing paradigms for drug discovery have focused largely on enzymes and other proteins as drug targets. In recent years, however, different varieties of ribonucleic acids have emerged as a viable focus for target-based drug discovery, with the potential to revolutionize the strategy and approach for this essential step in the drug development process. <p><i>RNA as a Drug Target: The Next Frontier for Medicinal Chemistry </i>offers a practice-oriented introduction to developing drug-like small molecules that selectively modulate both coding and non-coding RNAs. Beginning with a description and characterization of existing druggable RNAs, the book discusses how to approach different RNA targets for drug discovery. The result is a crucial resource for targeting RNAs and creating the next generation of life-saving pharmaceuticals. <p><i>RNA as a Drug Target </i>readers will also find: <ul><li>A complete “toolbox” for working with RNA, from structure determination to screening and lead generation techniques</li> <p><li>A wide range of addressable targets and mechanisms, including splicing modulation, riboswitches, targeted degradation, and more</li> <p><li>Authoritative discussion of the potential of RNA-targeted small molecule therapeutics for drugging the epitranscriptome</li></ul> <p><i>RNA as a Drug Target</i> provides an expert introduction to a new frontier in pharmaceutical research for medicinal chemists, biochemists, molecular biologists, and members of the pharmaceutical industry.

Diese Produkte könnten Sie auch interessieren:

Industrial Scale Inhibition
Industrial Scale Inhibition
von: Ibrahim Yahia Yaagoob, Chandrabhan Verma
EPUB ebook
211,99 €
Exploring Computational Pharmaceutics
Exploring Computational Pharmaceutics
von: Defang Ouyang
EPUB ebook
218,99 €
Industrial Scale Inhibition
Industrial Scale Inhibition
von: Ibrahim Yahia Yaagoob, Chandrabhan Verma
PDF ebook
211,99 €